Canadian Cannabis for GI Disease Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Medical cannabinoid products are widely used in Canada to treat medical symptoms of all kinds, and gastrointestinal (GI) symptoms are among the most commonly cited reasons for use. Cannabis is also widely used recreationally, and legalization of recreational use has occurred in Canada. Cannabis can be beneficial for individuals taking opioid medications for abdominal pain. Research shows that cannabis helps patients cut down on or eliminate their need for opioids and provides treatment with fewer side effects. Cannabis also helps individuals who have difficulty eating enough by increasing appetite and can help reduce diarrhoea and nausea.



Market Drivers

Key factors supporting the growth are rise in prevalence of cannabis intake for GI disease. The need to develop better product delivery systems and sustainable product strains. This need has, in turn, led to many companies coming up with R&D, which extensively investigates several genetic improvement strategies for cannabis. While the public opinion of cannabis has gone through many shifts, public interest in Canada has continued to grow in recent years. With the legalization of cannabis in Canada and more research, people are getting a deeper understanding of how cannabis works in humans.